Lithium Orotate for Alzheimer's Disease: A Feasibility Study
Part of Brain & nervous system clinical trials.
This trial tests whether a form of lithium called lithium orotate is safe and may help people with mild Alzheimer's disease. It looks at how the treatment affects brain proteins and thinking skills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Alzheimer's disease confirmed by a biomarker test (like a PET scan or spinal tap showing amyloid and tau proteins).
- Your Alzheimer's must be mild, meaning you have a Clinical Dementia Rating of 1 or less or a Quick Dementia Rating System score of 8 or less.
- You must be medically stable and able to attend all study visits and complete tests.
- If you take any psychiatric medicines, the doses must have been the same for at least 4 weeks before the first study visit.
- You cannot be currently receiving anti-amyloid monoclonal antibody therapy (like aducanumab or lecanemab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.
This study tests whether a treatment (atomoxetine or metformin) can help people with Alzheimer's disease maintain an improved state for at least 18 months. It may help you or a loved one stabilize symptoms and slow disease progression.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.